Benzodiazepines' Role in Managing Gastrointestinal Disorders

Richard Balon^a Nicoletta Sonino^{b, c} Chiara Rafanelli^d

^aDepartments of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University School of Medicine, Detroit, MI, USA; ^bDepartment of Statistical Sciences, University of Padova, Padua, Italy; ^cDepartment of Psychiatry, University at Buffalo, State University of New York, Buffalo, NY, USA; ^dDepartment of Psychology, University of Bologna, Bologna, Italy

Benzodiazepines (BZs) have been used broadly in gastroenterology, for instance in treating anxiety symptomatology associated with gastrointestinal (GI) illness, or in treating some underlying conditions (e.g., addressing alcohol dependence in liver disease), or in various diagnostic endoscopy procedures, and in preparation for surgery. It is known that anxiety and GI symptomatology/disorders frequently co-exist, with anxiety exacerbating GI disorders, and some GI symptoms provoking anxiety.

Association of Anxiety and GI Symptomatology

The complex relationship between anxiety and GI symptomatology has attracted limited attention over the years. In a study by Esler and Goulston [1] patients with the irritable-colon syndrome who had predominantly diarrhea were significantly more anxious and more neurotic than the control population of general medical patients. When analyzing results of the Epidemiological Catchment Area study, Walker et al. [2] compared subjects reporting unexplained GI symptoms to those not reporting any GI symptoms. Subjects reporting at least one unexplained GI symptoms were significantly more likely to have experienced lifetime episodes of panic disorder

(2.5% vs. 0.7%), agoraphobia (10.0% vs. 3.6%), and major depression (7.5% vs. 2.9%) when compared to subjects with no unexplained GI symptoms. The lifetime prevalence rate differences were even higher for subjects with two unexplained GI symptoms: 5.2% for panic disorder, 17.8% for agoraphobia, and 13.4% for major depression. In her review, Spinelli [3] concluded that approximately 40–60% of the patients with irritable bowel syndrome (IBS) have one or more concomitant psychiatric disorder, with anxiety, depression, and somatoform disorders being the most common, and that psychosocial stress exacerbates GI symptoms, including symptoms of IBS. In a study on anxiety and depressive symptoms and medical illness among adults with anxiety disorders, Niles et al. [4] found that anxiety was independently associated with having ulcer and that severity of anxiety and depressive symptoms was strongly associated with having more medical conditions. They felt that a bidirectional relation between anxiety and various diseases is likely. Goodwin and Stein [5] found a strong relationship between generalized anxiety disorder and peptic ulcer disease (PUD) (five-fold increase over people without generalized anxiety disorder). In his review on anxiety and medical illness, Schuckit [6] suggested that three GI problems (colitis, ulcer, and IBS) may be exacerbated by anxiety.

Potential Mechanisms

The mechanism of the bidirectional relationship between anxiety and GI illness/symptomatology is not understood and has not been sufficiently investigated. In his review of this relationship, Clouse [7] postulated interaction of emotional or other stressful, non-intestinal stimuli on GI tract function and possible direct relation of these stimuli to some GI illnesses, with mechanisms being both neural and humoral. He wrote that “The substrate for modulation of the GI tract by anxiety and other psychiatric disorders is provided by our knowledge of central nervous system control mechanisms of gastrointestinal functions”: [7, p.414]. Other investigators [8] emphasized the role of stress in PUD. However, since the discovery of the role of *Helicobacter pylori* in the etiology of PUD, the interest in studying the role of stress in this entity decreased though many recognize its multicausal etiology, including stress and unhealthy lifestyle. Interestingly, some indirect evidence of the impact of anxiety on GI symptomatology comes from studies examining the impact of BZs on various aspects of GI functioning.

Birnbaum et al. [9] found that oral administration of 10 mg of diazepam markedly reduced nocturnal human basal gastric secretion in duodenal ulcer patients when compared to placebo. They postulated that, since the decrease in secretion was achieved by a drug that has no anticholinergic effect in vitro, the mechanism should refer to regulatory autonomic functions in the central nervous system [9]. One may wonder whether the decrease of anxiety and/or the improved sleep were the causative factors.

It is well known that anxiety, especially chronic one, increases smooth muscles tension throughout the human body, including the GI system. It is commonly believed that this is centrally mediated though we do not have full understanding of this process. Benzodiazepine tetrazepam (used as muscle relaxant) relieved spasm of isolated rat duodenum and guinea pig ileum [10], which suggests peripheral involvement. On the other hand, intravenous diazepam decreased the pressure of lower esophageal sphincter in humans [11] that may suggest both peripheral (myogenic influence) and central (anxiety) mechanism. These findings suggest the possibility of using BZs for relieving spasm of musculature within the GI system. It would probably make sense to use longer-acting BZs such as clonazepam rather than short-acting ones (e.g., alprazolam), considering constant and continuous changes in GI motility and tone.

Increasingly important areas to consider in the involvement of anxiety in GI symptomatology are the regulatory function of the brain-gut axis [12] and the impact of the microbiota [13], especially in view of the mentioned [4] bi-directional relationship between anxiety and GI symptomatology/illness. The brain receives constant stream of interoceptive input from the GI tract and after integrating them sends response back to different GI tract cells, including the mentioned GI smooth muscle cells [12]. The brain can modulate the afferent signals from the GI system by endogenous pain facilitation or reduced endogenous pain inhibition [12], and may play a role in painful GI symptomatology; e.g., in IBS. Clearly, alteration of homeostatic reflexes could be associated with alteration in various GI functions, such as secretion and motility, thus leading to abdominal pain, discomfort, and alteration of bowel habits [12]. The regulation of the gut includes the sympathetic and parasympathetic nervous system, the hypothalamic-pituitary-adrenal axis, and involves various neurotransmitters, including the gamma-aminobutyric acid [13]. Various gut signaling (in both directions) could be influenced by numerous neurotransmitters, and the release of some of them, such as gamma-aminobutyric acid, could be influenced by BZs.

The mechanism of anxiety involvement in GI symptoms/disorders though widely known is not well understood. It seems, however, that medications such as BZs, may alleviate GI symptoms, possibly both centrally and peripherally.

BZ Use and Efficacy

Most of the studies examining the use of BZs in the treatment of GI symptomatology were done during the 1970s and 1980s.

In 1973, Baume and Cuthbert [14] noted that medazepam was significantly better than placebo in relieving major symptom complexes of functional bowel disease; e.g., aerophagy, nervous dyspepsia, and GI pain of 30 patients in a double-blind cross-over clinical trial. Expanding their research on BZs in GI symptoms, Baume et al. [15] compared diazepam (5 mg b.i.d.) and lorazepam (1 mg b.i.d.) to placebo in a double-blind, cross-over study of 28 patients with functional GI symptoms. Both BZs were significantly better than placebo. The authors noted that lorazepam (at that time it was fairly new medication) was well tolerated.

Lorazepam was found to be useful in the treatment of GI illness with anxiety component in several other stud-

ies. Kasich [16] reported that lorazepam (0.5–4.0 mg/day) was better than placebo and comparable to diazepam (2.5–30 mg/day) in a double-blind parallel treatment study of 120 patients with chronic GI disease associated with anxiety. The author concluded that lorazepam is an effective, safe, and useful adjunct in the management of functional and organic GI disorders where anxiety has negative influence. Chaplan and Vanov [17] found lorazepam significantly more helpful than placebo in 61 anxious patients with demonstrable “organic” or “functional” GI diseases in a double-blind placebo-controlled study of lorazepam (mean daily dose 3 mg). Lorazepam was helpful not just in relieving anxiety, but also in some GI symptoms, such as heartburn, constipation, aerophagia, bad taste, and others. Finally, Stokes [18] reported that lorazepam was effective in a double-blind placebo comparison of lorazepam. The initial dose of lorazepam was 3 mg/day; 21% of the patients were on a higher dose at the end of the study. The improvement was significantly greater with lorazepam than with placebo on all measures (anxiety, global, and GI symptomatology).

The place of BZs in the management of GI symptoms/illness was also examined in studies combining BZs with other medications used in the treatment of GI problems. Hüscher et al. [19] studied ranitidine and prazepam or ranitidine and placebo in a double-blind study of 50 patients with an active, endoscopically proven duodenal ulcer. At the end of their 4-week study, duodenal ulcer healed in 95.6% of the patients on ranitidine + prazepam and 75% of the patients on ranitidine + placebo ($p = 0.03$) (there were 2 dropouts in the prazepam group and 1 in the placebo group). Combination of octatropine methylbromide (anticholinergic agent) and diazepam (40/2.5 mg twice daily) in patients with IBS was not significantly different from placebo in a study by Pace et al. [20].

It is important to note that the side effects in all mentioned studies were usually mild, mostly sedation and sleepiness.

The evidence from these studies suggests an important role of BZs in managing various GI symptoms and disorders.

BZs versus Antidepressants

Considering their favorable side effects profile, BZs should be preferred to antidepressants in the management of GI symptoms with anxiety. BZs are usually not associated with GI side effects, while antidepressants are frequently associated with a number of adverse events.

Tricyclic antidepressants, effective in the treatment of functional GI disorders [21, 22], also in conjunction with cognitive behavioral therapy [23], may cause constipation. Second-generation antidepressants, such as SSRI and SNRI, may have a more profound unfavorable impact [24, 25], causing nausea, vomiting, dyspepsia, diarrhea, and abdominal pain [24]. Even short-term use of SSRI may be significantly associated with GI bleeding, suggesting that the same precautions that are used with non-steroidal anti-inflammatory drugs and aspirin are appropriate [25]. As a result, newer-generation antidepressants do not seem to be suitable for the treatment of anxiety associated with GI symptomatology, and BZs should be preferred.

Conclusion

The role of BZs in the management of various troublesome GI symptoms (e.g., aerophagia and GI pain), or some acute and chronic GI disorders (e.g., PUD, colitis, and IBS), has not been fully appreciated. Their use should be expanded. In addition to anxiety frequently accompanying these conditions, BZs, especially the long-acting ones, may, through either decreased gastric secretion and/or relaxation of smooth muscles tone, alleviate GI symptomatology, and contribute to patient well-being. The use of BZs in GI disorders may facilitate a transition of patients from pharmacotherapy to psychotherapy, which is an effective treatment particularly for functional symptoms [26, 27], and may provide more enduring results.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

The authors have no funding sources to declare.

Author Contributions

All authors contributed equally.

References

- Esler MD, Goulston KJ. Levels of anxiety in colonic disorders. *N Engl J Med*. 1973 Jan; 288(1):16–20.
- Walker EA, Katon WJ, Jemelka RP, Roy-Byrne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study. *Am J Med*. 1992 Jan;92(1 1A):26S–30S.
- Spinelli A. Irritable bowel syndrome. *Clin Drug Investig*. 2007;27(1):15–33.
- Niles AN, Dour HJ, Stanton AL, Roy-Byrne PP, Stein MB, Sullivan G, et al. Anxiety and depressive symptoms and medical illness among adults with anxiety disorders. *J Psychosom Res*. 2015 Feb;78(2):109–15.
- Goodwin RD, Stein MB. Generalized anxiety disorder and peptic ulcer disease among adults in the United States. *Psychosom Med*. 2002 Nov-Dec;64(6):862–6.
- Schuckit MA. Anxiety related to medical disease. *J Clin Psychiatry*. 1983 Nov;44(11 Pt 2):31–7.
- Clouse RE. Anxiety and gastrointestinal illness. *Psychiatr Clin North Am*. 1988 Jun; 11(2):399–417.
- Wolf S, Almy TP, Bachrach WH, Spiro HM, Sturdevant RA, Weiner H. The role of stress in peptic ulcer disease. *J Human Stress*. 1979 Jun;5(2):27–37.
- Birnbaum D, Karmeli F, Tefera M. The effect of diazepam on human gastric secretion. *Gut*. 1971 Aug;12(8):616–8.
- Pérez-Guerrero C, Suárez J, Herrera MD, Marhuenda E. Spasmolytic effects of tetrazepam on rat duodenum and guinea-pig ileum. *Pharmacol Res*. 1997 May;35(5):493–7.
- Rushnak MJ, Leevy CM. Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study. *Am J Gastroenterol*. 1980 Feb;73(2):127–30.
- Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. *Annu Rev Med*. 2011;62(1):381–96.
- Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. *J Clin Invest*. 2015 Mar; 125(3):926–38.
- Baume P, Cuthbert J. The effect of medazepam in relieving symptoms of functional gastrointestinal distress. *Aust N Z J Med*. 1973 Oct;3(5):457–60.
- Baume P, Tracey M, Dawson L. Efficacy of two minor tranquilizers in relieving symptoms of functional gastrointestinal distress. *Aust N Z J Med*. 1975 Dec;5(6):503–6.
- Kasich AM. Lorazepam in the management of anxiety associated with chronic gastrointestinal disease: a double-blind study. *Curr Ther Res Clin Exp*. 1976 Mar;19(3):292–306.
- Chaplan A, Vanov SK. GI illness: treatment of the anxiety component. *Psychosomatics*. 1977 Oct;18(4):49–54.
- Stokes DK Jr. Lorazepam in anxiety associated with chronic enteritis and ulcerative colitis. *J Clin Psychiatry*. 1978 Oct;39(10 Pt 2):53–7.
- Hüscher C, Magni G, Salmi A, Bossini S, Felini C, Besozzi F, et al. Ranitidine versus ranitidine and prazepam in the short-term treatment of duodenal ulcer—a double-blind controlled trial. *Eur J Clin Pharmacol*. 1985; 28(2):177–80.
- Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, et al. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. *Eur Rev Med Pharmacol Sci*. 2010 Mar;14(3):155–62.
- Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. *Am J Med*. 2000 Jan;108(1):65–72.
- Clouse RE. Antidepressants for functional gastrointestinal syndromes. *Dig Dis Sci*. 1994 Nov;39(11):2352–63.
- Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology*. 2003 Jul;125(1):19–31.
- Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. *Psychother Psychosom*. 2016; 85(5):270–88.
- Wang YP, Chen YT, Tsai CF, Li SY, Luo JC, Wang SJ, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. *Am J Psychiatry*. 2014 Jan; 171(1):54–61.
- Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2016 Jul;14(7):937–947.e4.
- Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. *Clin Psychol Rev*. 2017 Feb;51:142–52.